Daily filing brief

10 Important BSE and NSE Announcements for 15 September 2026

By Daily BrieferPublished Updated

UNO Minda announced four expansions with total estimated investment of ₹1,415 crore, while Vodafone Idea reported Q1 FY27 revenue of Rs11,689 crore. Our 15 September 2026 edition also includes Titagarh Rail Systems' agreement with BHEL to establish a JV for maintaining 80 Vande Bharat Trainsets.

  1. UNO Minda Ltd-$

    Uno Minda announces four major strategic expansions with ₹1,415 crore investment

    Press Release / Media Release

    Investment and expansions overview

    • Total investment across four expansions estimated at ₹1,415 crore.
    • Greenfield Aluminium Casting Facility at Hosur capex ₹510 crore.
    • Hosur capacity to 30,000 MT at peak.
    • Phase 1 production by Q4FY28; consolidation by Q1FY29.
    • Kharkhoda expansion adds 3.3 million units; relocate 2.0 million from Supa.
    • Kharkhoda capex ₹155 crore; Phase 1 by Q4FY28.
    • Total investment across four expansions to strengthen manufacturing footprint.

    Schedule and scope details

    • Greenfield Hosur facility consolidates existing operations by Q1FY29.
    • New Hosur plant enables EV/powertrain, 1.0 Mn HPDC two-wheeler alloy wheels.
    • Kharkhoda plant diversifies North India alloy wheel capacity.
    • Phase 1 production for both facilities targeted by Q4FY28.
    • Combined capex for Hosur and Kharkhoda projects ₹665 crore.
    View source

  2. Vodafone Idea Ltd

    Vodafone Idea Q1 FY27 revenue Rs11,689 crore; debt down, ARPU up, brand refresh and 5G expansion

    Investor Presentation

    Business Overview

    • Vi is a telecom operator with 193+ million subscribers and 209,000+ sites.
    • Brand refresh underway; Shah Rukh Khan named as brand ambassador.
    • 1-2-3 strategy and 17-5-5 network play.

    Operational Highlights

    • Q1 FY27 metrics show improving ARPU and data usage.
    • Broadband sites at 205k; ARPU at Rs195.
    • 4G/5G subs at 130.1 million; data usage 88.4 Pb/day.
    • Enterprise growth with AI-enabled services; 2,700+ retail stores.

    Financial Performance

    • Q1 FY27 revenue Rs11,689 crore; EBITDA Rs5,034 crore.
    • Subscriber base EOP ~193.1 million; ARPU Rs195; data usage 88.4 Pb/day.
    • Debt from Banks reduced to Rs211 crore; cash Rs6,558 crore.
    • Capex in Q1 FY27: Rs1,930 crore.

    Capital Structure & Liquidity

    • NCDs outstanding: Rs3,278 crore.
    • Credit ratings stable: Crisil A-; ICRA A-.

    Strategic Priorities & Outlook

    • Pursuing 1-2-3 strategy; 5G expansion across all 17 circles.
    • Brand refresh with SRK to drive momentum.
    • AI-enabled services, cloud, and IoT; expanding enterprise solutions.
    • Retail footprint expanding to 2,700+ stores; emphasis on service differentiation.

    Governance & Leadership

    • Credit ratings and brand governance cited; no material leadership changes disclosed.
    View source

  3. Titagarh Rail Systems Ltd

    Titagarh Rail Systems to form 50:50 JV with BHEL for Vande Bharat trainset maintenance

    Memorandum of Understanding /Agreements

    Parties and structure

    • Titagarh Rail Systems Ltd and Bharat Heavy Electricals Limited sign the JVA.
    • JV ownership: 50% TRSL and 50% BHEL.
    • Initial paid-up capital: INR 50 lakh; Delhi registered office.
    • Board composition: two directors from each party.

    Purpose and scope

    • Purpose: establish a JV to maintain 80 Vande Bharat Trainsets.
    • Term: 35-year comprehensive maintenance program.
    • JVC to enhance lifecycle management and collaboration with Indian Railways.

    Related party and governance

    • No related party status; no promoter-group involvement.
    • Not a related party transaction; arms-length not applicable.
    • Incorporation of JVC subject to applicable regulatory approvals.
    • Annexures A and B contain disclosures; to be updated on exchanges.

    Impact and disclosures

    • Expected to expand TRSL's participation across rolling stock value chain.
    • Facilitates technical collaboration, synergies, and lifecycle management.
    • Strategic long-term relationship with Indian Railways.
    • No management changes disclosed at this time.
    View source

  4. Piramal Finance Ltd

    Piramal Finance Q1 FY27: AUM growth 32% YoY, total income ₹1,693 Cr, net profit ₹461 Cr, robust liquidity

    Investor Presentation

    Business overview

    • Piramal Finance runs a multi-product retail and wholesale lending platform.
    • AI-native blueprint aims to lift AUM scale and productivity.
    • Merged with Piramal Enterprises; integration effective from Sep 2025.

    Key operational highlights

    • Retail AUM up 32% YoY to ₹91,249 Cr; disbursements +44% YoY.
    • Total AUM ₹95,369 Cr; growth led by retail and new products.
    • Gold loan program: Phase 1 rolled out; Phase 2 expansion planned.
    • Cross-sell: unsecured disbursals cross-sell 25-30% of unsecured disbursements.
    • Piramal.ai adoption: multiple AI use cases across underwriting, CX, and collections.

    Financial performance

    • Total income ₹1,693 Cr; net profit ₹461 Cr; PPOP ₹804 Cr in Q1 FY27.
    • QoQ: income up 9%; YoY: PPOP up 89%, net profit up 67%.
    • Retail AUM 91,249 Cr; Wholesale AUM 13,238 Cr; AUM mix 85:15.
    • LCR at 553%; provision coverage ~2.3% of total AUM; CIR improving.

    Capital structure & liquidity

    • Gross debt ₹82,345 Cr; net worth ₹28,906 Cr; cash ₹6,925 Cr.
    • Total assets ₹111,251 Cr; capital adequacy 18.85%.
    • Consolidated LCR 553% on a period-average basis.

    Strategic priorities & outlook

    • AI-native growth agenda; Piramal.ai across underwriting, CX, collections.
    • Growth AUM strategy; multi-product retail platform across risk-reward spectrum.
    • Rural and urban expansion; branch network widening in Tier 2/3 markets.

    Risks & governance

    • Forward-looking statements carry regulatory and provisioning risks; mitigated by robust framework.
    • Legacy AUM now ~2% of total; merger integration risk managed.
    View source

  5. Aurobindo Pharma Ltd

    USFDA grants final approval for Beclomethasone Dipropionate MDI; first inhalation product for Aurobindo

    Press Release / Media Release

    Key developments

    • USFDA final approval to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg.
    • First MDI product for Aurobindo, enabling expansion into complex respiratory therapies.
    • Manufacturing at Raleigh facility; Aurolife Pharma LLC subsidiary.
    • Launch expected in upcoming quarters.
    • IQVIA estimates US market size US$301 million for 12 months ended July 2026.
    • Cumulative USFDA ANDA approvals total 596, with 571 final and 25 tentative.
    View source

  6. Embassy Developments Ltd

    Embassy Developments unveils Embassy Origins in North Bengaluru with ₹4,500 crore GDV and RERA approvals

    Press Release / Media Release

    Overview

    • Launch of Embassy Origins is an ~85-acre residential development in North Bengaluru.
    • First phase comprises two RERA-approved projects: Embassy Riverine (217 villas) and Embassy South Reserve (855 apartments).
    • Combined GDV for the first phase is ~₹4,500 crore.
    • Total saleable area across both projects exceeds 2.6 million sq ft.
    • RERA approvals granted for Riverine and South Reserve.
    • Design incorporates ~4,000 trees across 100–120 species with a green spine.
    • Immersive residential experience centre unveiled for customer engagement.
    • Located about 20 minutes from Kempegowda International Airport.
    • Development connected to key Bengaluru destinations and ecosystem.
    View source

  7. Novartis India Ltd

    Novartis India holds first Investor Meet post-takeover; outlines growth plan, M&A, and governance.

    Analyst / Investor Meet

    Meeting Details

    • Sept 11, 2026, 4:00 PM IST; Analyst/Institutional Investors’ Call; virtual and physical.
    • Audio recording submitted to stock exchange on Sept 12, 2026; transcript available on NIL site.

    Participants

    • CEO & MD: Dr. Vikas Gupta
    • CFO: Bhagwat Deora
    • President, M&A, BD and IR: Jason D'Souza
    • CHRO: Rahul Vijayvargiya
    • Independent Directors: Chairperson Ramesh; Suchita Sharma; Shashank Sinha
    • Non-Executive Directors: Kshitij Sheth; Jagriti Gupta

    Purpose

    • Present NIL post-takeover growth strategy focused on six anchor therapy areas.
    • Discuss strengthened promotion, pan-India distribution, and governance framework.
    • Share long-term targets, including growth beyond market, with M&A as key driver.

    Additional Notes

    • Minipress XL acquired from Pfizer; strengthens cardiology portfolio.
    • Ophthalmology in-licensing: Pagenax, Accentrix; upfront INR 10 crores; total portfolio ~INR 100 crores.
    • ChrysCapital holds 70.68% stake; open offer at INR 860.64; tendered Jun 11–24.
    • FY27 run-rate about INR 650 crores; target doubling in 4–5 years; payback 8–9 years; IRR ~12–12.5%.
    • Name-change under consideration; shareholder approvals; product brands remain.
    View source

  8. Neuland Laboratories Ltd

    Neuland accelerates peptide manufacturing expansion as first module becomes operational.

    Press Release / Media Release

    Module 1 operational

    • First commercial peptide manufacturing module is now operational, enabling 7000 L reactor capacity.

    Module 2 expansion plan

    • Module 2 capacity slated up to 18,000 L with three LPPS reactors.

    Capex and future investments

    • USD 30 million invested in Module 1; additional investments planned for later modules.

    Revenue context

    • Revenues rose 116% in the most recent quarterly results.

    Capacity context

    • Total reactor capacity across Neuland facilities about 1,218 kL.

    Market trajectory

    • Oncology programs emerging as a key growth area; outsourcing demand expanding.

    Strategic outlook

    • Management intends to align capacity with demand over the next decade.
    View source

  9. K M Sugar Mills Ltd

    NCLT sanctions demerger of Distillery Division into wholly owned subsidiary with 1:5 share swap and listing plan

    Scheme of Arrangement

    Overview

    • Demerger of a Distillery Division from the parent into its wholly owned subsidiary.

    Rationale

    • Segregates Distillery Division for focused operations and separate listing.

    Key Terms

    • Nature and structure: demerger of a division into the listed standalone entity.
    • Share exchange: 1 new Rs10 share per 5 Demerged Rs2 shares.
    • Appointed Date: 01-Apr-2026; Effective Date/Record Date to be fixed.
    • Related party: Demerged and Resulting are related; replica shareholding proposed.
    • Approvals: NCLT sanction obtained; stock exchanges to grant in-principle approvals.
    • Assets/Liabilities transfer: Distillery assets and liabilities transfer; Remaining Business stays with parent.
    • Listing: Resulting Company to be listed; Demerged Company to remain listed.

    Financial Impact

    • Capital structure: Authorized capital raised to Rs 20 crore for Resulting Company.
    • Pre/post scheme: Demerged assets/liabilities transfer; investment in Resulting Company canceled; replica shares issued.
    • Accounting: assets/liabilities recorded at book values; intercompany balances adjusted.
    • Taxation: Liabilities and taxes on the Demerged Undertaking treated as those of Resulting Company; GAAR reserved.
    • Record Date: Appointed Date 01-Apr-2026; Record Date to be fixed; Effective Date after sanction.
    • Share entitlements: New Shares issued to Demerged Company's shareholders; existing Resulting Company capital canceled.

    Stakeholder Impact

    • Shareholders receive New Shares in Resulting Company proportional to holdings.
    • Creditors: transferred liabilities; security arrangements maintained.
    • Employees: transfer to Resulting Company on same terms; retirement/benefits recognized.
    • Operations/structure: Distillery division becomes standalone; Remaining Business continues with Demerged Company.
    • Listing: both entities to be listed on major exchanges; timelines subject to approvals.

    Status & Next Steps

    • Sanction: NCLT order dated 19-08-2026; Scheme binding on all concerned.
    • Effective/Record Date: Appointed Date 01-04-2026; Effective Date to be communicated.
    • Regulatory approvals: SEBI/Stock Exchanges in-principle; further filings required.
    • Record Date/Notice: Board to announce record date; SEBI/Listing compliance.
    View source

  10. Kavveri Defence & Wireless Technologies Ltd-$

    Defense order worth INR 222 crore under production; INR 20 crore executed to date

    Award of Order / Receipt of Order

    Order execution update

    • Awarding entity: Defence Sector.
    • Nature and scope: Design, development, manufacture, and supply of antennas, filters, switches, and RF components.
    • Order value: INR 222 crores (aggregate).
    • Geography: India and overseas defence customers.
    • Execution window: 2–3 months.
    • Status: Currently under production.
    • Value executed to date: INR 20 crores.
    • Balance value: INR 222 crores.
    • Expected completion: 3 months.
    • Impact: Expected to meaningfully lift reported revenue as orders are executed.
    View source